TY - JOUR T1 - Human lung tissue resident memory T cells are re-programmed but not eradicated with systemic glucocorticoids after acute cellular rejection JF - medRxiv DO - 10.1101/2021.09.27.21263985 SP - 2021.09.27.21263985 AU - Mark E. Snyder AU - Kaveh Moghbeli AU - Anna Bondonese AU - Andrew Craig AU - Iulia Popescu AU - Li Fan AU - Tracy Tabib AU - Robert Lafyatis AU - Kong Chen AU - Humberto E. Trejo Bittar AU - Elizabeth Lendermon AU - Joseph Pilewski AU - Bruce Johnson AU - Silpa Kilaru AU - Yingze Zhang AU - Pablo G. Sanchez AU - Jonathan K. Alder AU - Peter A. Sims AU - John F. McDyer Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/09/29/2021.09.27.21263985.abstract N2 - Acute cellular rejection is common after lung transplantation and is associated with an increased risk of early chronic rejection. We present combined single cell RNA and T cell receptor sequencing on recipient derived T cells obtained from the bronchoalveolar lavage of three lung transplant recipients with acute cellular rejection and compare them with T cells obtained from the same three patients after clinical treatment of rejection with high-dose, systemic glucocorticoids. At the time of acute cellular rejection, we find an oligoclonal expansion of cytotoxic CD8+ T cells, that all persist as tissue resident memory T cells following successful treatment. Persisting CD8+ allograft-resident T cells have reduced gene expression for cytotoxic mediators following therapy with glucocorticoids. This clonal expansion is discordant with circulating T cell clonal expansion at the time of rejection, suggesting in-situ expansion. These findings pose a potential biological mechanism linking acute cellular rejection to chronic allograft damage.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by a NIH K23 HL151750-01 awarded to M.E.S, and an NIH 1R01HL133184 awarded to JM.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Institutional Review Board (study number: STUDY20060250) at the University of Pittsburgh.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw data were generated at the University of Pittsburgh and are included in the article and supplementary materials. The complete set of raw data supporting the findings of this study are available from the corresponding author MES on request.(ACR)Acute Cellular Rejection(CLAD)Chronic lung allograft dysfunction(TRM)Tissue resident memory T cell(MLR)Mixed Lymphocyte Reaction(BAL)Bronchoalveolar lavage ER -